MA40309A1 - Anticorps anti-cd73 et leurs utilisations - Google Patents
Anticorps anti-cd73 et leurs utilisationsInfo
- Publication number
- MA40309A1 MA40309A1 MA40309A MA40309A MA40309A1 MA 40309 A1 MA40309 A1 MA 40309A1 MA 40309 A MA40309 A MA 40309A MA 40309 A MA40309 A MA 40309A MA 40309 A1 MA40309 A1 MA 40309A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- relates
- antibodies according
- human
- internalization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Abstract
La présente invention concerne des anticorps monoclonaux isolés, en particulier des anticorps humains, qui se lient au marqueur de différenciation 73 (cd73) humain avec une grande affinité et inhibent l'activité du cd73, et éventuellement gèrent l'internalisation du cd73 dépendant des anticorps. L'invention concerne également des molécules d'acide nucléique codant pour les anticorps selon l'invention, des vecteurs d'expression, des cellules hôtes et des procédés pour exprimer les anticorps selon l'inventi
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083056P | 2014-11-21 | 2014-11-21 | |
PCT/US2015/061639 WO2016081748A2 (fr) | 2014-11-21 | 2015-11-19 | Anticorps anti-cd73 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40309A1 true MA40309A1 (fr) | 2018-01-31 |
Family
ID=55022668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40309A MA40309A1 (fr) | 2014-11-21 | 2017-05-19 | Anticorps anti-cd73 et leurs utilisations |
Country Status (36)
Country | Link |
---|---|
US (6) | US10100129B2 (fr) |
EP (2) | EP3725808A1 (fr) |
JP (2) | JP6805142B2 (fr) |
KR (2) | KR102569813B1 (fr) |
CN (2) | CN113773388A (fr) |
AR (1) | AR102698A1 (fr) |
AU (2) | AU2015349878A1 (fr) |
BR (1) | BR112017010110A2 (fr) |
CA (1) | CA2968357A1 (fr) |
CL (2) | CL2017001296A1 (fr) |
CO (1) | CO2017005845A2 (fr) |
CY (1) | CY1123355T1 (fr) |
DK (1) | DK3221363T3 (fr) |
EA (2) | EA035766B1 (fr) |
ES (1) | ES2807182T3 (fr) |
HK (1) | HK1244817A1 (fr) |
HR (1) | HRP20201176T1 (fr) |
HU (1) | HUE050596T2 (fr) |
IL (2) | IL252353B (fr) |
LT (1) | LT3221363T (fr) |
MA (1) | MA40309A1 (fr) |
ME (1) | ME03806B (fr) |
MX (1) | MX2017006624A (fr) |
MY (1) | MY189836A (fr) |
NZ (1) | NZ731633A (fr) |
PE (1) | PE20170782A1 (fr) |
PH (1) | PH12017500918A1 (fr) |
PL (1) | PL3221363T3 (fr) |
PT (1) | PT3221363T (fr) |
RS (1) | RS60631B1 (fr) |
SG (2) | SG11201703192SA (fr) |
SI (1) | SI3221363T1 (fr) |
TN (1) | TN2017000203A1 (fr) |
TW (2) | TWI711630B (fr) |
UY (1) | UY36404A (fr) |
WO (1) | WO2016081748A2 (fr) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2618292T3 (es) | 2008-01-31 | 2017-06-21 | Inserm - Institut National De La Sante Et De La Recherche Medicale | Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras |
US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
US9938356B2 (en) | 2014-11-10 | 2018-04-10 | Medimmune Limited | Binding molecules specific for CD73 and uses thereof |
KR102569813B1 (ko) * | 2014-11-21 | 2023-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
EP3789399A1 (fr) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Anticorps comprenant des régions constantes de chaîne lourde modifiées |
EP3362475B1 (fr) | 2015-10-12 | 2023-08-30 | Innate Pharma | Agents de blocage de cd73 |
EP3407917A1 (fr) * | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Conjugués d'anticorps anti-cd74, compositions comprenant des conjugués d'anticorps anti-cd74 et méthodes d'utilisations desdits conjugués d'anticorps anti-cd74 |
SG10201913033UA (en) * | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
EP3470424A4 (fr) * | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | Séquence de région constante à chaîne lourde d'anticorps pour améliorer l'activité d'anticorps agonistes |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
WO2018009916A1 (fr) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugués d'adjuvant d'anticorps |
WO2018013611A1 (fr) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anticorps anti-cd73 |
CN107698684B (zh) * | 2016-08-03 | 2021-09-28 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白 |
US20190175755A1 (en) * | 2016-08-23 | 2019-06-13 | The Johns Hopkins University | Immunoswitch nanoparticles for reprogrammed t cell responses |
WO2018049083A1 (fr) * | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Anticorps contre des épitopes spécifiques à l'oxydation |
AR109770A1 (es) * | 2016-10-18 | 2019-01-23 | Lilly Co Eli | ANTICUERPOS DEL RECEPTOR II DE TGF-b |
CA3045466A1 (fr) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-pd-l1 radiomarques pour imagerie immuno-pet |
MX2019006897A (es) | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
CN110290810A (zh) | 2016-12-13 | 2019-09-27 | 博尔特生物治疗药物有限公司 | 抗体佐剂缀合物 |
AU2018213549B2 (en) * | 2017-01-24 | 2022-02-03 | I-Mab Biopharma Co., Ltd. | Anti-CD73 antibodies and uses thereof |
CA3051640A1 (fr) | 2017-03-16 | 2018-09-20 | Innate Pharma | Compositions et methodes pour le traitement du cancer |
CN113480655B (zh) * | 2017-03-28 | 2022-05-31 | 礼进生物医药科技(上海)有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
WO2018187512A1 (fr) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Méthodes de traitement des tumeurs à taux de cd73 élevés |
ES2939384T3 (es) | 2017-04-14 | 2023-04-21 | Bolt Biotherapeutics Inc | Método de síntesis de inmunoconjugados |
US20200147210A1 (en) * | 2017-05-11 | 2020-05-14 | The General Hospital Corporation | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
CN110753703B (zh) | 2017-05-23 | 2024-04-09 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | 新的cd73抗体、其制备和用途 |
WO2018217976A1 (fr) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Anticorps monoclonaux antagonistes anti-cd40 et leurs utilisations |
WO2018237157A1 (fr) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
WO2019068907A1 (fr) | 2017-10-06 | 2019-04-11 | Innate Pharma | Restauration de l'activité de lymphocytes t par l'axe cd39/cd73 |
CA3076872A1 (fr) * | 2017-11-03 | 2019-05-09 | Novartis Ag | Anticorps anti-cd40 destines a etre utilises dans le traitement du syndrome de sjogren |
EP3717907A1 (fr) | 2017-11-30 | 2020-10-07 | Novartis AG | Récepteur d'antigène chimérique ciblant le bcma et ses utilisations |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶 |
CN110240654A (zh) * | 2018-03-07 | 2019-09-17 | 复旦大学 | 结合cd73的抗体-药物偶联物 |
WO2019170131A1 (fr) * | 2018-03-07 | 2019-09-12 | 复旦大学 | Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes |
EP3762030A4 (fr) * | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | Anticorps anti-cd73 et utilisations associées |
WO2019173692A2 (fr) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anticorps anti-cd73 et leurs procédés d'utilisation |
US11873341B2 (en) * | 2018-03-13 | 2024-01-16 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
JP2021520201A (ja) * | 2018-04-04 | 2021-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cd27抗体およびその使用 |
CN112218657A (zh) | 2018-04-12 | 2021-01-12 | 百时美施贵宝公司 | Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法 |
CA3100544A1 (fr) | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugues |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
EP3569618A1 (fr) * | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonisation d'anticorps cd73 |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (fr) * | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
CA3098420A1 (fr) | 2018-06-01 | 2019-12-05 | Novartis Ag | Molecules de liaison dirigees contre bcma et leurs utilisations |
WO2019243252A1 (fr) | 2018-06-18 | 2019-12-26 | Innate Pharma | Compositions et méthodes pour le traitement du cancer |
WO2020020307A1 (fr) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anticorps bispécifiques anti-cd73 anti-pd-l1 |
US20210187115A1 (en) | 2018-08-29 | 2021-06-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting EGFR |
WO2020069382A1 (fr) * | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Molécules de liaison anti-cd137 comprenant des domaines fc modifiés et leurs utilisations thérapeutiques |
JP2022509930A (ja) * | 2018-11-12 | 2022-01-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗cd73抗体、その抗原結合フラグメントおよびそれらの使用 |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技(成都)有限公司 | 一种抗cd73单克隆抗体及其应用 |
CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
WO2020190734A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le pd-l1 |
WO2020190731A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
US20220152215A1 (en) | 2019-03-15 | 2022-05-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting CEA |
CA3142640A1 (fr) * | 2019-06-06 | 2020-12-10 | Jacobio Pharmaceuticals Co., Ltd. | Molecule de liaison specifique a cd73 et utilisation de la molecule de liaison |
CA3142887A1 (fr) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Composes d'aminobenzazepine, immunoconjugues et leurs utilisations |
CN117946274A (zh) * | 2019-06-19 | 2024-04-30 | 海正生物制药有限公司 | 抗cd73抗体及其应用 |
CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
JP7471016B2 (ja) * | 2019-08-21 | 2024-04-19 | ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド | 抗cd73抗体およびその適用 |
KR20220050971A (ko) * | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
WO2021046112A1 (fr) | 2019-09-03 | 2021-03-11 | Bolt Biotherapeutics, Inc. | Composés aminoquinoline, immunoconjugués et leurs utilisations |
WO2021046347A1 (fr) | 2019-09-04 | 2021-03-11 | Bolt Biotherapeutics, Inc. | Procédé de synthèse d'immunoconjugué |
CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
JP2022547081A (ja) * | 2019-09-06 | 2022-11-10 | シンフォジェン・アクシェセルスケープ | 抗cd73抗体 |
EP4031578A1 (fr) | 2019-09-18 | 2022-07-27 | Novartis AG | Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies |
BR112022006001A2 (pt) | 2019-09-30 | 2022-07-12 | Bolt Biotherapeutics Inc | Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado |
US20220362299A1 (en) * | 2019-10-21 | 2022-11-17 | Purdue Research Foundation | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibiton techniques |
KR20220088901A (ko) | 2019-10-25 | 2022-06-28 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 티에노아제핀 면역접합체, 및 이의 용도 |
TW202128768A (zh) * | 2020-01-03 | 2021-08-01 | 美商英塞特公司 | 抗cd73抗體及其用途 |
TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Cd73抑制劑及a2a/a2b腺苷受體抑制劑組合療法 |
WO2021150702A1 (fr) | 2020-01-21 | 2021-07-29 | Bolt Biotherapeutics, Inc. | Anticorps anti-pd-l1 |
EP4093510A1 (fr) | 2020-01-21 | 2022-11-30 | Bolt Biotherapeutics, Inc. | Anticorps anti-pd-l1 |
WO2021173832A1 (fr) | 2020-02-25 | 2021-09-02 | Bolt Biotherapeutics, Inc. | Méthodes de traitement du cancer |
US20230174665A1 (en) * | 2020-04-09 | 2023-06-08 | Aprilbio Co., Ltd. | Monoclonal Antibodies and Antigen Binding Fragments Thereof for Suppressing CD73 Immune Checkpoint and Uses Thereof |
CA3176321A1 (fr) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anticorps bispecifique anti-cd73-anti-pd-1 et son utilisation |
BR112022021397A2 (pt) * | 2020-04-22 | 2023-02-07 | Akeso Biopharma Inc | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma |
KR20230005907A (ko) | 2020-05-01 | 2023-01-10 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 항-dectin-2 항체 |
US20230293716A1 (en) | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
JP2023525827A (ja) * | 2020-05-12 | 2023-06-19 | 普米斯生物技術(珠海)有限公司 | 抗cd73抗体およびその使用 |
WO2021247188A1 (fr) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Essai d'activité biologique antagoniste de cd73 et procédés d'utilisation de celui-ci |
AU2021297856A1 (en) * | 2020-06-22 | 2023-02-02 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-CD73 antibody and use thereof |
WO2022010539A1 (fr) * | 2020-07-08 | 2022-01-13 | Octagon Therapeutics, Inc. | Modulateurs de cellules cancéreuses |
AU2021326516A1 (en) | 2020-08-13 | 2023-04-13 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
AU2021326889A1 (en) * | 2020-08-17 | 2023-03-23 | Akeso Biopharma, Inc | Anti-CD73 antibody and use thereof |
CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
CN112251463B (zh) * | 2020-09-30 | 2023-06-06 | 广东药康生物科技有限公司 | 一种cd73人源化小鼠模型的构建方法 |
KR20230104651A (ko) | 2020-11-06 | 2023-07-10 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
CN117264060A (zh) * | 2020-11-09 | 2023-12-22 | 江苏中新医药有限公司 | 抗胞外-5’-核苷酸酶的抗体及其在制备肿瘤药物中的应用 |
CN115052894A (zh) * | 2020-11-27 | 2022-09-13 | 科望(苏州)生物医药科技有限公司 | 靶向cd39和tgfbeta的新型缀合物分子 |
JP2023552792A (ja) | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗her2免疫複合体、及びその使用 |
CN116897054A (zh) | 2020-12-11 | 2023-10-17 | 博尔特生物治疗药物有限公司 | 抗her2免疫缀合物及其用途 |
TW202222840A (zh) * | 2020-12-11 | 2022-06-16 | 大陸商上海華奧泰生物藥業股份有限公司 | Cd73的抗原結合蛋白及其應用 |
US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
CN116723866A (zh) | 2020-12-11 | 2023-09-08 | 博尔特生物治疗药物有限公司 | 抗pd-l1免疫缀合物和其用途 |
JP2024501453A (ja) | 2020-12-11 | 2024-01-12 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ceaイムノコンジュゲート、及びそれらの使用 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
EP4271384A1 (fr) | 2020-12-29 | 2023-11-08 | Incyte Corporation | Polythérapie comprenant des inhibiteurs a2a/a2b, des inhibiteurs pd-1/pd-l1 et des anticorps anti-cd73 |
JP2024505600A (ja) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | 結合剤およびそれを使用する方法 |
WO2022178416A1 (fr) * | 2021-02-22 | 2022-08-25 | Northwestern University | Anticorps monoclonaux anti-cd73 |
EP4299589A1 (fr) * | 2021-02-24 | 2024-01-03 | Novoprotein Scientififc Inc. | Anticorps anti-cd73 humain et son utilisation |
WO2022204536A1 (fr) | 2021-03-26 | 2022-09-29 | Bolt Biotherapeutics, Inc. | Immunoconjugués de 2-amino-4-carboxamide-benzazépine et leurs utilisations |
IL306114A (en) | 2021-03-26 | 2023-11-01 | Bolt Biotherapeutics Inc | 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof |
WO2022235569A1 (fr) * | 2021-05-05 | 2022-11-10 | Corvus Pharmaceuticals, Inc. | Composés anti-cd73 pour traiter des cancers positifs aux oncovirus |
TW202317048A (zh) | 2021-07-01 | 2023-05-01 | 美商愛德華生命科學公司 | 心臟瓣膜修復裝置及其遞送裝置 |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
CA3234604A1 (fr) | 2021-10-29 | 2023-05-04 | Shelley Erin ACKERMAN | Immunoconjugues agonistes de tlr avec des anticorps mutants de cysteine, et leurs utilisations |
WO2023143227A1 (fr) * | 2022-01-25 | 2023-08-03 | 石药集团巨石生物制药有限公司 | Anticorps anti-cd73 et son utilisation |
WO2023174213A1 (fr) * | 2022-03-14 | 2023-09-21 | 上海华奥泰生物药业股份有限公司 | Conjugué anticorps-médicament et son utilisation |
WO2023201267A1 (fr) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop-2 |
CN115991772B (zh) * | 2022-08-12 | 2023-09-01 | 南京蓬勃生物科技有限公司 | 抗cd73抗体或其抗原片段及其应用 |
WO2024040194A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
CN116813786A (zh) * | 2023-08-03 | 2023-09-29 | 贝达药业股份有限公司 | 抗cd73抗体及其应用 |
Family Cites Families (292)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (fr) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2061566C (fr) | 1992-02-20 | 2002-07-09 | Rudolf E. Falk | Traitement des maladies par l'acide hyaluronique et des ains |
CA2061703C (fr) | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Compositions renfermant de l'acide hyaluronique |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2124967C (fr) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Animaux transgeniques non humains capables de produire des anticorps heterologues |
CA2130762C (fr) | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Traitement des maladies et des troubles associes a l'infiltration par des macrophages |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
CA2161351C (fr) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Animaux transgeniques, pouvant produire des anticorps heterologues |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
AU1444095A (en) | 1993-12-27 | 1995-07-17 | Baxter International Inc. | Water soluble non-immunogenic polyamide cross-linking agents |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
EP0862553A4 (fr) | 1995-10-03 | 1999-02-03 | Scripps Research Inst | Analogues de cbi de cc-1065 et des duocarmycines |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
EP1724282B1 (fr) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Procédé de production de protéines non-immunogènes |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
SI1068241T1 (sl) | 1998-04-02 | 2007-12-31 | Genentech Inc | Protitelesne variante in njihovi fragmenti |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
PL200134B1 (pl) | 1999-05-07 | 2008-12-31 | Genentech Inc | Zastosowanie przeciwciała anty-CD20 |
US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
JP4118462B2 (ja) | 1999-07-19 | 2008-07-16 | 株式会社リコー | 携帯電子機器 |
EP1074563A1 (fr) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Polypeptides chimériques augmentant la formation de dimères par des interactions électrostatiques et des ponts disulfures, méthode pour les produire et leurs utilisations |
US6936704B1 (en) | 1999-08-23 | 2005-08-30 | Dana-Farber Cancer Institute, Inc. | Nucleic acids encoding costimulatory molecule B7-4 |
EP1212422B1 (fr) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Anticorps contre l'antigene ctla-4 humain et utilisation |
WO2001022920A2 (fr) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Polynucleotides et polypeptides associes au colon et au cancer du colon |
CA3016482A1 (fr) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | Nouvelle molecule immunoregulatrice b7-h1, |
ATE407950T1 (de) | 1999-12-23 | 2008-09-15 | Zymogenetics Inc | Löslicher interleukin-20 rezeptor |
DK1616575T3 (da) | 1999-12-23 | 2012-09-10 | Zymogenetics Inc | Fremgangsmåde til behandling af inflammation |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
US20070042392A1 (en) | 2000-02-03 | 2007-02-22 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
EP1252192B1 (fr) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps |
KR20020091170A (ko) | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용 |
HUP0002003A3 (en) | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
NO20002685A (no) | 2000-05-25 | 2001-10-15 | Viggo Wahl Pedersen | Spylemekanisme for vannklosett |
WO2002004613A2 (fr) | 2000-07-07 | 2002-01-17 | University Of North Carolina At Chapel Hill | Polynucleotides isoles codant les 5'-nucleotidases cn-ia et cn-ib humaines, proteines isolees codees par ces polynucleotides, et procedes d'utilisation |
ES2564161T3 (es) | 2000-07-11 | 2016-03-18 | Research Corporation Technologies, Inc | Polipéptidos de anticuerpos artificiales |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
WO2002092780A2 (fr) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules |
KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
EP1443961B1 (fr) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Compositions de glycoproteine |
US6545530B1 (en) | 2001-12-05 | 2003-04-08 | Linear Technology Corporation | Circuit and method for reducing quiescent current in a voltage reference circuit |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2003074679A2 (fr) | 2002-03-01 | 2003-09-12 | Xencor | Optimisation d'anticorps |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CA2495251C (fr) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Anticorps specifiques du recepteur fc.gamma.riib et procedes d'utilisation de ces anticorps |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
WO2004079013A1 (fr) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) utilisee dans le diagnostic et le traitement du cancer du pancreas |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
CN102940889A (zh) | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CN1829533A (zh) | 2003-05-30 | 2006-09-06 | 阿莱克申药物公司 | 包含改造恒定区的抗体和融合蛋白 |
JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
US7473531B1 (en) | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
WO2005019258A2 (fr) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
US7329353B2 (en) | 2004-01-23 | 2008-02-12 | Amgen Inc. | LC/MS method of analyzing high molecular weight proteins |
EP1737890A2 (fr) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Variantes d'immunoglobuline a l'exterieur de la region fc |
US7778814B2 (en) | 2004-03-30 | 2010-08-17 | Siemens Aktiengesellschaft | Method and device for simulating an automation system |
CA2564076C (fr) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Bras de liaison chimiques et conjugues associes |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
DK1776384T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006047350A2 (fr) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | Variants d'immunoglobuline igg a fonction effectrice optimisee |
JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EA010654B1 (ru) | 2004-11-23 | 2008-10-30 | Пи Ай Пи Ко., Лтд. | Вмонтированная в стену распределительная коробка водоснабжения |
US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2970873C (fr) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
KR101386494B1 (ko) | 2005-05-10 | 2014-04-24 | 인사이트 코포레이션 | 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법 |
EP1896503B1 (fr) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | ANTICORPS D'ISOTYPE IgG1 MUTÉS DANS LEUR PARTIE Fc AFIN D'AUGMENTER LEUR LIAISON AVEC LE FcRn ET LEUR UTILISATION |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
WO2007038868A2 (fr) | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Nouveau compose d'enediyne et ses utilisations |
CA2627046C (fr) | 2005-10-26 | 2015-09-15 | Medarex, Inc. | Procede et composes pour la preparation d'analogues de cc-1065 |
US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
CA2627190A1 (fr) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Composes et conjugues cytotoxiques |
JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環 |
PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
AR061181A1 (es) | 2006-05-25 | 2008-08-13 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
DE102006027624A1 (de) | 2006-06-13 | 2007-12-20 | Elexxion Gmbh | Handstück für insbesondere medizinische Laseranwendungen |
WO2007148417A1 (fr) | 2006-06-21 | 2007-12-27 | Oncotherapy Science, Inc. | Anticorps monoclonaux de ciblage tumoral dirigés contre la fzd10 et leurs utilisations |
US20150030534A1 (en) | 2013-07-26 | 2015-01-29 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
EP2975057A1 (fr) | 2006-07-10 | 2016-01-20 | Fujita Health University | Nouvel anticorps anti-cd73 |
WO2008036642A2 (fr) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
WO2008140603A2 (fr) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
TW200900059A (en) | 2007-02-21 | 2009-01-01 | Medarex Inc | Chemical linkers with single amino acids and conjugates thereof |
JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
WO2008147143A2 (fr) | 2007-05-30 | 2008-12-04 | Postech Academy-Industry Foundation | Protéines de fusion d'immunoglobuline |
BRPI0815567B8 (pt) | 2007-07-17 | 2021-05-25 | Merck Patent Gessellschaft Mit Beschraenkter Haftung | anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica |
WO2009014708A2 (fr) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation |
DE102007036200A1 (de) | 2007-08-02 | 2009-02-05 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech |
CA3128656A1 (fr) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Polypeptides de liaison activables et procedes d'identification et utilisation de ceux-ci |
MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
CN101939425B (zh) * | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
BRPI0817637A2 (pt) | 2007-09-28 | 2015-09-08 | Chugai Pharmaceutical Co Ltd | anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma |
CA2700860C (fr) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Anticorps humains qui se lient a la mesotheline, et utilisations de ceux-ci |
EP2203180B1 (fr) * | 2007-10-22 | 2012-11-21 | Merck Serono S.A. | Ifn-bêta unique fusionné à un fragment fc d'igg muté |
FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Faron Pharmaceuticals Oy | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
WO2009073546A2 (fr) | 2007-11-30 | 2009-06-11 | Medarex, Inc. | Conjugués anticorps monoclonal-molécules partenaires dirigés contre la protéine tyrosine kinase 7 (ptk7) |
EP2224958A2 (fr) | 2007-11-30 | 2010-09-08 | Bristol-Myers Squibb Company | Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés |
EP2227233B1 (fr) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Inhibiteurs de l'ido |
RU2531521C2 (ru) | 2007-12-05 | 2014-10-20 | Чугаи Сейяку Кабусики Кайся | Антитело против nr10 и его применение |
WO2009079242A2 (fr) | 2007-12-05 | 2009-06-25 | Massachusetts Institute Of Technology | Mutants d'immunoglobuline aglycosylée |
ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
AU2008353145B2 (en) | 2008-01-03 | 2013-09-12 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
JP5608100B2 (ja) | 2008-02-08 | 2014-10-15 | メディミューン,エルエルシー | 低下したFcリガンド親和性を有する抗IFNAR1抗体 |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
AU2009237662A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
EP2282773B1 (fr) | 2008-05-02 | 2014-01-15 | Seattle Genetics, Inc. | Procédé et compositions pour préparer des anticorps et des dérivés d'anticorps avec une fucosylation centrale réduite |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
JP2012511033A (ja) | 2008-12-08 | 2012-05-17 | テゴファーム コーポレーション | 多価化合物の可逆阻害用マスキングリガンド |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
EP2481752B1 (fr) | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Régions constantes modifiées d'un anticorps |
WO2011056652A1 (fr) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Dérivés imidazole comme inhibiteurs de l'ido |
JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
LT2954779T (lt) | 2009-12-10 | 2019-05-27 | Regeneron Pharmaceuticals, Inc. | Pelės, gaminančios sunkiosios grandinės antikūnus |
TR201906650T4 (tr) | 2010-02-08 | 2019-05-21 | Regeneron Pharma | Ortak hafif zincirli fare. |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
CN103038251B (zh) | 2010-02-19 | 2016-08-17 | Xencor公司 | 新颖ctla4-ig免疫粘附素 |
CA2791658C (fr) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Anticorps reagissant avec b7-h3, fragments immunologiquement actifs associes et utilisations associees |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
MX341925B (es) | 2010-03-29 | 2016-09-07 | Zymeworks Inc | Anticuerpos con funcion efectora suprimida o mejorada. |
DK2558491T3 (en) | 2010-04-13 | 2018-10-15 | Bristol Myers Squibb Co | Fibronectin-based Scaffold domain proteins that bind PCSK9 |
US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
WO2011131246A1 (fr) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Composés et utilisations de ceux-ci pour induire la mort d'une cellule cancéreuse immunogène chez un sujet |
WO2011131472A1 (fr) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Composés et leurs utilisations pour induire la mort d'une cellule cancéreuse immunogène chez un sujet |
US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
WO2012007783A1 (fr) | 2010-07-13 | 2012-01-19 | Institut Gustave Roussy | Trousses et procédés de détection de la capacité à induire une mort cellulaire cancéreuse immunogène chez un patient |
EP2561088A1 (fr) | 2010-04-22 | 2013-02-27 | Institut Gustave Roussy | Composés et leurs utilisations pour induire la mort d'une cellule cancéreuse immunogène chez un sujet |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
WO2011140249A2 (fr) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Anticorps liant csf1r |
RS58736B1 (sr) | 2010-06-22 | 2019-06-28 | Regeneron Pharma | Miševi koji ispoljavaju imunoglobinski hibrid lakog lanca sa ljudskom varijabilnom regijom |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US20130123345A1 (en) | 2010-07-23 | 2013-05-16 | The Ohio State University | Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway |
CA2806252C (fr) | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Anticorps dont les points isoelectriques sont modifies |
EP3248987A1 (fr) | 2010-07-30 | 2017-11-29 | Novartis AG | Molécules de berceau de fibronectine et leurs banques |
WO2012031320A1 (fr) | 2010-09-06 | 2012-03-15 | Peter Maccallum Cancer Institute | Diagnostic du cancer |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
US9328160B2 (en) | 2010-10-29 | 2016-05-03 | Perseus Proteomics Inc. | Anti-CDH3 antibody having high internalization capacity |
WO2012087928A2 (fr) | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulation d'anticorps agonistes anti-tnfr |
SG191977A1 (en) * | 2011-02-01 | 2013-08-30 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
PT2697257T (pt) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Proteínas de fusão fc compreendendo novos ligantes ou arranjos |
NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 | ||
CA2833636A1 (fr) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Anticorps et autres molecules qui se lient a b7-h1 et a pd-1 |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
KR101860174B1 (ko) | 2011-09-20 | 2018-05-21 | 메디뮨 리미티드 | 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀 |
US20130149300A1 (en) | 2011-09-27 | 2013-06-13 | Icon Genetics Gmbh | MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS |
ES2402038B1 (es) | 2011-10-14 | 2013-11-25 | Josep Ramon Viola Terès | Base para palé y palé provisto de esta |
US20140371427A1 (en) | 2011-12-07 | 2014-12-18 | Amgen Inc. | IgG2 DISULFIDE ISOFORM SEPARATION |
CN104159921B (zh) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
SG10202001596VA (en) | 2011-12-19 | 2020-04-29 | Univ Rockefeller | Non-sialylated anti-inflammatory polypeptides |
EP2807194A4 (fr) | 2012-01-27 | 2015-12-02 | Gliknik Inc | Protéines de fusion comprenant des domaines charnières igg2 |
RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
PE20141791A1 (es) | 2012-02-13 | 2014-11-19 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
US9943574B2 (en) | 2012-06-27 | 2018-04-17 | Arthrogen B.V. | Combination for treating an inflammatory disorder |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
RU2718751C2 (ru) | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r) |
CN104768969B (zh) | 2012-09-13 | 2021-04-16 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
WO2014126836A1 (fr) | 2013-02-14 | 2014-08-21 | Bristol-Myers Squibb Company | Composés de tubulysine, procédés d'élaboration et d'utilisation correspondants |
WO2014153424A1 (fr) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines) |
KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
CN103278634B (zh) * | 2013-05-16 | 2015-01-07 | 中国科学院近代物理研究所 | Cd73作为肾透明细胞癌干细胞表面标志物的应用 |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
CN107172880B (zh) | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
MA39986A (fr) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
SG11201610074YA (en) | 2014-06-06 | 2016-12-29 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EP3736294A3 (fr) | 2014-10-10 | 2021-02-17 | Innate Pharma | Blocage de cd73 |
US9938356B2 (en) | 2014-11-10 | 2018-04-10 | Medimmune Limited | Binding molecules specific for CD73 and uses thereof |
GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
EP3789399A1 (fr) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Anticorps comprenant des régions constantes de chaîne lourde modifiées |
KR102569813B1 (ko) | 2014-11-21 | 2023-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
EA201891121A1 (ru) | 2015-11-19 | 2018-12-28 | Бристол-Майерс Сквибб Компани | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения |
SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
CA3064321A1 (fr) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Anticorps comprenant des regions constantes de chaine lourde modifiees |
EP3630832A1 (fr) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Domaines fc d'igg1 modifiés et fusions d'anticorps de domaine anti-cd40 avec ces derniers |
WO2018217976A1 (fr) | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Anticorps monoclonaux antagonistes anti-cd40 et leurs utilisations |
CN112218657A (zh) | 2018-04-12 | 2021-01-12 | 百时美施贵宝公司 | Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法 |
EP3887397A1 (fr) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Anticorps comprenant des régions constantes de chaîne lourde modifiées |
-
2015
- 2015-11-19 KR KR1020177016541A patent/KR102569813B1/ko active IP Right Grant
- 2015-11-19 SI SI201531307T patent/SI3221363T1/sl unknown
- 2015-11-19 RS RS20200915A patent/RS60631B1/sr unknown
- 2015-11-19 CN CN202111102059.8A patent/CN113773388A/zh active Pending
- 2015-11-19 SG SG11201703192SA patent/SG11201703192SA/en unknown
- 2015-11-19 UY UY0001036404A patent/UY36404A/es unknown
- 2015-11-19 AR ARP150103765A patent/AR102698A1/es unknown
- 2015-11-19 BR BR112017010110-6A patent/BR112017010110A2/pt not_active Application Discontinuation
- 2015-11-19 EA EA201790986A patent/EA035766B1/ru not_active IP Right Cessation
- 2015-11-19 PT PT158162768T patent/PT3221363T/pt unknown
- 2015-11-19 CA CA2968357A patent/CA2968357A1/fr active Pending
- 2015-11-19 PL PL15816276T patent/PL3221363T3/pl unknown
- 2015-11-19 EA EA202090956A patent/EA202090956A3/ru unknown
- 2015-11-19 ME MEP-2020-157A patent/ME03806B/fr unknown
- 2015-11-19 LT LTEP15816276.8T patent/LT3221363T/lt unknown
- 2015-11-19 EP EP20164125.5A patent/EP3725808A1/fr active Pending
- 2015-11-19 CN CN201580063448.0A patent/CN107001474B/zh active Active
- 2015-11-19 EP EP15816276.8A patent/EP3221363B1/fr active Active
- 2015-11-19 TW TW104138281A patent/TWI711630B/zh active
- 2015-11-19 MX MX2017006624A patent/MX2017006624A/es unknown
- 2015-11-19 NZ NZ731633A patent/NZ731633A/en unknown
- 2015-11-19 DK DK15816276.8T patent/DK3221363T3/da active
- 2015-11-19 AU AU2015349878A patent/AU2015349878A1/en not_active Abandoned
- 2015-11-19 ES ES15816276T patent/ES2807182T3/es active Active
- 2015-11-19 SG SG10201913004UA patent/SG10201913004UA/en unknown
- 2015-11-19 JP JP2017527316A patent/JP6805142B2/ja active Active
- 2015-11-19 WO PCT/US2015/061639 patent/WO2016081748A2/fr active Application Filing
- 2015-11-19 MY MYPI2017701826A patent/MY189836A/en unknown
- 2015-11-19 HU HUE15816276A patent/HUE050596T2/hu unknown
- 2015-11-19 US US15/520,638 patent/US10100129B2/en active Active
- 2015-11-19 TW TW109137987A patent/TWI758928B/zh active
- 2015-11-19 PE PE2017000897A patent/PE20170782A1/es unknown
- 2015-11-19 KR KR1020237028104A patent/KR20230125855A/ko active Application Filing
- 2015-11-19 TN TN2017000203A patent/TN2017000203A1/en unknown
-
2016
- 2016-01-13 US US14/994,828 patent/US9605080B2/en active Active
-
2017
- 2017-02-14 US US15/432,180 patent/US10167343B2/en active Active
- 2017-05-17 IL IL252353A patent/IL252353B/en active IP Right Grant
- 2017-05-18 PH PH12017500918A patent/PH12017500918A1/en unknown
- 2017-05-19 MA MA40309A patent/MA40309A1/fr unknown
- 2017-05-19 CL CL2017001296A patent/CL2017001296A1/es unknown
- 2017-06-14 CO CONC2017/0005845A patent/CO2017005845A2/es unknown
-
2018
- 2018-03-06 HK HK18103196.6A patent/HK1244817A1/zh unknown
- 2018-05-25 CL CL2018001414A patent/CL2018001414A1/es unknown
- 2018-08-27 US US16/113,061 patent/US20190055320A1/en not_active Abandoned
- 2018-08-30 US US16/117,183 patent/US11352440B2/en active Active
-
2020
- 2020-07-28 HR HRP20201176TT patent/HRP20201176T1/hr unknown
- 2020-08-04 CY CY20201100722T patent/CY1123355T1/el unknown
- 2020-12-03 JP JP2020200743A patent/JP7235712B2/ja active Active
-
2021
- 2021-06-14 IL IL283965A patent/IL283965A/en unknown
- 2021-08-13 AU AU2021215286A patent/AU2021215286A1/en active Pending
-
2022
- 2022-05-05 US US17/737,403 patent/US20230051701A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40309A1 (fr) | Anticorps anti-cd73 et leurs utilisations | |
PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
PH12018500657A1 (en) | Optimized variants of anti-vegf antibodies | |
EA202091566A1 (ru) | Содержащая нуклеиновую кислоту липидная наночастица и ее применение | |
MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
EP3736294A3 (fr) | Blocage de cd73 | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MA37407A1 (fr) | Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
MA38194A1 (fr) | Anticorps anti-ceacam5 et leurs utilisations | |
WO2014194282A3 (fr) | Molécules fvii-xten chimères et leurs utilisations | |
MA38828A1 (fr) | Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations | |
MA44081B1 (fr) | Anticorps anti-c5 et leurs procédés d'utilisation | |
TW200716174A (en) | Anti-MCP-1 antibodies, compositions, methods and uses | |
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
EA201890941A1 (ru) | Программируемые универсальные клеточные рецепторы и способы их применения | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
MX2019013370A (es) | Constructos de anticuerpos de ácidos nucleicos optimizados. | |
CR20210094A (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) | |
EA201491471A1 (ru) | Состав, содержащий антитело против ил-17 | |
MA42640A1 (fr) | Protéines de fusion de dmdv et e2 et leurs utilisations | |
MA46988A1 (fr) | Formulation liquide d'anticorps anti-tnf alpha | |
MA40371A (fr) | Sélectivité efficace des protéines recombinées |